TV ad for the new lubricant eye drops opens with a man in a desert background saying: "Imagine a world without moisture. For millions of people with dry, scratchy eyes, this is how their world feels...Now there's new Visine Tears for dry eyes, with a unique tears formula not found in other leading brands." Over a likeness of a dry, cracked-looking eye, the narrator says the product "soothes dry scratchy eyes and makes them feel moist and comfortable in seconds, and it's safe to use as often as you need." The ad concludes with the narrator stating, "Discover a world of comfort with new Visine Tears. It gets the dry out." Pfizer also is promoting the product to eye care professionals through sampling and journal print ads. The product was launched in mid-January ("The Tan Sheet" Jan. 18, p. 4)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys. Discussions on safety of DMD treatment for non-ambulatory patients is ongoing.
While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.
Average sales prices, and Medicare spending on some drugs, would be expected to be lower, CMS says in the Physician Fee Schedule proposed rule.
